DE60109960D1 - 8-substituierte 2,6-methano-3-benzazocine und 3-substituierte morphinane als opioidrezeptorbindende agenzien - Google Patents

8-substituierte 2,6-methano-3-benzazocine und 3-substituierte morphinane als opioidrezeptorbindende agenzien

Info

Publication number
DE60109960D1
DE60109960D1 DE60109960T DE60109960T DE60109960D1 DE 60109960 D1 DE60109960 D1 DE 60109960D1 DE 60109960 T DE60109960 T DE 60109960T DE 60109960 T DE60109960 T DE 60109960T DE 60109960 D1 DE60109960 D1 DE 60109960D1
Authority
DE
Germany
Prior art keywords
substituted
methano
morphinanes
benzazocine
receptor binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60109960T
Other languages
English (en)
Other versions
DE60109960T2 (de
Inventor
P Wentland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rensselaer Polytechnic Institute
Original Assignee
Rensselaer Polytechnic Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rensselaer Polytechnic Institute filed Critical Rensselaer Polytechnic Institute
Application granted granted Critical
Publication of DE60109960D1 publication Critical patent/DE60109960D1/de
Publication of DE60109960T2 publication Critical patent/DE60109960T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
DE60109960T 2000-10-31 2001-10-31 8-substituierte 2,6-methano-3-benzazocine und 3-substituierte morphinane als opioidrezeptorbindende agenzien Expired - Lifetime DE60109960T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24443800P 2000-10-31 2000-10-31
US244438P 2000-10-31
PCT/US2001/045581 WO2002036573A2 (en) 2000-10-31 2001-10-31 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents

Publications (2)

Publication Number Publication Date
DE60109960D1 true DE60109960D1 (de) 2005-05-12
DE60109960T2 DE60109960T2 (de) 2006-02-16

Family

ID=22922766

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60109960T Expired - Lifetime DE60109960T2 (de) 2000-10-31 2001-10-31 8-substituierte 2,6-methano-3-benzazocine und 3-substituierte morphinane als opioidrezeptorbindende agenzien
DE60133584T Expired - Lifetime DE60133584T2 (de) 2000-10-31 2001-10-31 4-arylpiperidine als opioidrezeptorbindende agenzien

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60133584T Expired - Lifetime DE60133584T2 (de) 2000-10-31 2001-10-31 4-arylpiperidine als opioidrezeptorbindende agenzien

Country Status (9)

Country Link
US (9) US6784187B2 (de)
EP (3) EP1353909B1 (de)
JP (2) JP4340437B2 (de)
AT (2) ATE391712T1 (de)
AU (2) AU2002227135B2 (de)
CA (1) CA2426942C (de)
DE (2) DE60109960T2 (de)
ES (3) ES2572332T3 (de)
WO (1) WO2002036573A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1353909B1 (de) 2000-10-31 2005-04-06 Rensselaer Polytechnic Institute 8-substituierte 2,6-methano-3-benzazocine und 3-substituierte morphinane als opioidrezeptorbindende agenzien
US6974824B2 (en) * 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
WO2003097608A2 (en) * 2002-05-17 2003-11-27 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7501433B2 (en) 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7923454B2 (en) 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
CN1758912A (zh) * 2003-03-07 2006-04-12 东丽株式会社 药物·物质依赖治疗药
US7381721B2 (en) 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US6992090B2 (en) 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
EA015491B1 (ru) 2003-06-27 2011-08-30 Янссен Фармацевтика Н.В. ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ
EP1595541A1 (de) 2004-05-12 2005-11-16 Alcasynn Pharmaceuticals Gmbh Verwendung von Opioid-Rezeptor Antagonisten zur Vorbeugung und/oder Behandlung von Krankheiten die im zusammenhang mit den Angrifftspunkt Calcineurin stehen
US7244866B2 (en) * 2004-05-14 2007-07-17 Janssen Pharmaceutical N.V. Carboxamido opioid compounds
KR20080027216A (ko) 2004-08-05 2008-03-26 얀센 파마슈티카 엔.브이. 트리사이클릭 δ-오피오이드 조절자
AR053098A1 (es) * 2004-11-04 2007-04-25 Toray Industries Analgesico derivado de morfinano
KR101115841B1 (ko) * 2004-11-05 2012-03-09 렌슬러 폴리테크닉 인스티튜트 4-하이드록시벤조모르판
KR20070087675A (ko) 2004-12-22 2007-08-28 얀센 파마슈티카 엔.브이. 트리사이클릭 δ-오피오이드 모듈레이터
CA2591963A1 (en) 2004-12-22 2006-06-29 Janssen Pharmaceutica N.V. Tricyclic o-opioid modulators
AU2006203880A1 (en) 2005-01-06 2006-07-13 Janssen Pharmaceutica N.V. Tricyclic delta-opioid modulators
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
WO2006138528A2 (en) 2005-06-16 2006-12-28 Janssen Pharmaceutica N.V Tricyclic opioid modulators
US7557119B2 (en) 2005-07-21 2009-07-07 Rensselaer Polytechnic Institute Large substituent, non-phenolic opioids
US7538110B2 (en) 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
TWI425945B (zh) * 2007-05-28 2014-02-11 Seldar Pharma Inc 四氫異喹啉－１－酮衍生物或其鹽
ES2586245T3 (es) * 2007-08-09 2016-10-13 Rensselaer Polytechnic Institute Carboxamidas cuaternarias opioides
EP2318372B9 (de) * 2008-07-21 2015-05-06 Rensselaer Polytechnic Institute Nichtphenolische aminopioide mit grossem substituenten
WO2010107457A1 (en) * 2009-03-19 2010-09-23 Alkermes, Inc. Morphinan derivatives with high oral bioavailability
WO2010151318A1 (en) 2009-06-22 2010-12-29 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8624040B2 (en) 2009-06-22 2014-01-07 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US10363251B2 (en) 2009-07-16 2019-07-30 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
TW201118084A (en) * 2009-09-18 2011-06-01 Adolor Corp The use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders
NZ600379A (en) * 2009-12-04 2014-05-30 Alkermes Pharma Ireland Ltd Morphinan derivatives for the treatment of drug overdose
US8546588B2 (en) * 2010-02-26 2013-10-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US20110212969A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
JP5964809B2 (ja) 2010-03-22 2016-08-03 レンセラール ポリテクニック インスティチュート オピオイド受容体リガンドとしてのカルボキサミド基を含有するモルヒネ誘導体
WO2011130163A1 (en) 2010-04-12 2011-10-20 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
ES2708726T3 (es) 2010-07-08 2019-04-10 Alkermes Pharma Ireland Ltd Proceso para la síntesis de morfinanos sustituidos
AU2010357625B2 (en) 2010-07-16 2015-04-23 Mallinckrodt Llc (+)-morphinans as antagonists of Toll-like receptor 9 and therapeutic uses thereof
CA2807965C (en) 2010-08-23 2016-03-15 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
US8471026B2 (en) 2010-08-26 2013-06-25 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012054332A1 (en) 2010-10-18 2012-04-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8778931B2 (en) 2010-12-22 2014-07-15 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012138888A1 (en) 2011-04-05 2012-10-11 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
LT2725908T (lt) 2011-06-29 2017-09-11 Alkermes, Inc. Periferinio poveikio opioidų junginiai
KR101996108B1 (ko) 2011-12-15 2019-10-01 엘커메스 파마 아일랜드 리미티드 부프레놀핀 및 뮤-오피오이드 수용체 길항물질의 조성물
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US10138207B2 (en) * 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof
CA2911231C (en) 2013-05-24 2021-12-07 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
EP3074379B1 (de) 2013-11-27 2019-06-26 Nektar Therapeutics (India) Pvt. Ltd. Opioid agonisten und deren verwendung
US9975854B2 (en) 2014-05-06 2018-05-22 Purdue Pharma L.P. Benzomorphan analogs and use thereof
AU2016215431B2 (en) 2015-02-02 2020-07-23 Valo Early Discovery, Inc. 3-aryl-4-amido-bicyclic (4,5,0) hydroxamic acids as HDAC inhibitors
TW201636329A (zh) 2015-02-02 2016-10-16 佛瑪治療公司 作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
WO2018125716A1 (en) * 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
EP4243768A1 (de) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Mehrschichttablette mit sofortiger freisetzung

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH581624A5 (de) 1970-08-14 1976-11-15 Sumitomo Chemical Co
US3856795A (en) 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4032529A (en) * 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4373139A (en) 1979-04-30 1983-02-08 Motorola, Inc. Detectors
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4374139A (en) * 1981-11-09 1983-02-15 Hoffmann-La Roche Inc. Levorotatory N-substituted acylmorphinans useful as analgesic agents
US4649200A (en) * 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
US4939264A (en) 1986-07-14 1990-07-03 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US5258386A (en) 1991-06-05 1993-11-02 The United States Of America As Represented By The Secretary Of The Army (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en) 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
SE9103745D0 (sv) * 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
EP0624095B2 (de) 1991-12-31 2005-07-20 Zymogenetics, Inc. Verfahren und zusammensetzungen zur verminderung von blutverlust
EP0632041A1 (de) * 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen Neue Morphin Derivate mit verbesserten analgetischen und narkotischen Eigenschaften
AR005423A1 (es) 1996-01-10 1999-06-23 Smithkline Beecham Spa Derivados morfinoides condensados con heterociclos (ii), su uso como sustancia terapeutica y para preparar medicamentos, composiciones farmaceuticasque los contienen y procedimiento para preparar dichos derivados.
GB9709972D0 (en) * 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
GB9912411D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
EP1353909B1 (de) * 2000-10-31 2005-04-06 Rensselaer Polytechnic Institute 8-substituierte 2,6-methano-3-benzazocine und 3-substituierte morphinane als opioidrezeptorbindende agenzien
WO2003101963A1 (en) 2002-05-30 2003-12-11 Eli Lilly And Company Opioid receptor antagonists
KR101115841B1 (ko) * 2004-11-05 2012-03-09 렌슬러 폴리테크닉 인스티튜트 4-하이드록시벤조모르판
US7557119B2 (en) * 2005-07-21 2009-07-07 Rensselaer Polytechnic Institute Large substituent, non-phenolic opioids

Also Published As

Publication number Publication date
US20040030138A1 (en) 2004-02-12
EP1353909A2 (de) 2003-10-22
US20060030580A1 (en) 2006-02-09
EP1359146A2 (de) 2003-11-05
AU2002227135B2 (en) 2008-01-03
WO2002036573B1 (en) 2003-09-25
JP4340437B2 (ja) 2009-10-07
US20030187009A1 (en) 2003-10-02
US20110207763A1 (en) 2011-08-25
ES2304477T3 (es) 2008-10-16
DE60109960T2 (de) 2006-02-16
US6887998B2 (en) 2005-05-03
ES2572332T3 (es) 2016-05-31
US20170217977A1 (en) 2017-08-03
EP1944292A1 (de) 2008-07-16
EP1944292B1 (de) 2016-02-17
US20120302591A1 (en) 2012-11-29
JP2004522706A (ja) 2004-07-29
US20050090519A1 (en) 2005-04-28
JP2004137288A (ja) 2004-05-13
US6784187B2 (en) 2004-08-31
EP1359146B1 (de) 2008-04-09
CA2426942C (en) 2014-06-03
ATE292625T1 (de) 2005-04-15
EP1944292B9 (de) 2016-07-06
DE60133584D1 (de) 2008-05-21
WO2002036573A2 (en) 2002-05-10
US20140275545A1 (en) 2014-09-18
US8642615B2 (en) 2014-02-04
US20090048447A1 (en) 2009-02-19
US9932349B2 (en) 2018-04-03
AU2713502A (en) 2002-05-15
US7265226B2 (en) 2007-09-04
CA2426942A1 (en) 2002-05-10
EP1353909B1 (de) 2005-04-06
WO2002036573A3 (en) 2003-08-21
ATE391712T1 (de) 2008-04-15
US7956187B2 (en) 2011-06-07
DE60133584T2 (de) 2009-06-04
US8252929B2 (en) 2012-08-28
EP1359146A3 (de) 2004-04-14
ES2239170T3 (es) 2005-09-16

Similar Documents

Publication Publication Date Title
DE60109960D1 (de) 8-substituierte 2,6-methano-3-benzazocine und 3-substituierte morphinane als opioidrezeptorbindende agenzien
CY1108918T1 (el) Φαρμακευτικοι συνδυασμοι οξυκωδονης και ναλοξονης
IL182983A0 (en) 4-hydroxybenzomorphans
CY1106099T1 (el) Φαρμακευτικη στοματικη δοσολογικη μορφη που πepιλαμβανει ενα συνδυασμο ενος οπιοειδους αγωνιστη και ναλτρεξονης
FR2809329B1 (fr) Concentrateur d'oxygene portable
BR0103322A (pt) Processo de preparo e uso de nanopartìculas de metal nobre
DE60029857D1 (de) Lichtempfindliche Zusammensetzung und 1,3-dihydro-1-oxo-2H-Indenderivat
EE200100458A (et) Ravimaine kombinatsioonis prootonpumba inhibiitori või H2 retseptori antagonistiga ning neid sisaldav farmatseutiline kompositsioon kasutamiseks mao-soolkonna häirete ravis
DE60016460D1 (de) Verwendungen und zusammenstellungen von nitratestern als sedativa
HK1068618A1 (en) Preparation of n1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
FR2827802B1 (fr) Dispositif d'usinage par etincelage combinant la perforation et le taraudage
ATE236169T1 (de) Heterocyclisch kondensierte morphinoid-derivate
IL160018A0 (en) Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
EP2072082A3 (de) N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3 sulfonamid als analgetikum
FR2797655B1 (fr) Patte d'ancrage d'huisserie, notamment d'huisserie metallique de porte ou de portail
WO2002046156A3 (en) 4,4-DISUBSTITUTED PIPERIDINES AND THEIR METHODS OF USE
DE69922918D1 (de) Neuropeptid Y Antagonisten
IT1315905B1 (it) Barra rotante blinda vano antirotazione dell'anta di infissi in genere
IT251056Y1 (it) Distributore automatico dotato di mezzi di identificazione e riconoscimento personale dell'utilizzatore.
RU2001129744A (ru) Способ лечения бациллярных форм туберкулеза легких
ITMS960004V0 (it) Sistema integrato a gestione vocale per il miglioramento dell'attivita lavorativa delle singola persona
ITMI20001495A0 (it) Sistema per ridurre l'ingombro dell'anta di porta in apertura.
UA7375S (uk) Прапор представницький «мітек»
EP1584333A3 (de) Verwendung von Acetylcoenzyme A Inhibitoren zur Behandlung von Alzheimer
UA4749S (uk) Комп`ютерний стіл «перспектива»

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH, 805